Literature DB >> 23596055

Weekly chemotherapy with radiation versus high-dose cisplatin with radiation as organ preservation for patients with HPV-positive and HPV-negative locally advanced squamous cell carcinoma of the oropharynx.

Irina Y Dobrosotskaya1, Emily Bellile, Matthew E Spector, Bhavna Kumar, Felix Feng, Avraham Eisbruch, Gregory T Wolf, Mark E P Prince, Jeffrey S Moyer, Theodoros Teknos, Douglas B Chepeha, Heather M Walline, Jonathan B McHugh, Kitrina G Cordell, P Daniel Ward, Serena Byrd, Jessica H Maxwell, Susan Urba, Carol R Bradford, Thomas E Carey, Francis P Worden.   

Abstract

BACKGROUND: Optimal treatment for locally advanced squamous cell carcinoma of the oropharynx (SCCOP) is not well defined. Here we retrospectively compare survival and toxicities from 2 different organ preservation protocols.
METHODS: The matched dataset consisted of 35 patients from each trial matched for age, stage, smoking, and tumor human papillomavirus (HPV) status. Patients in the University of Michigan Cancer Center (UMCC) trial 9921 were treated with induction chemotherapy (IC) followed by high-dose cisplatin and radiation in responders or surgery in nonresponders. Patients in the UMCC trial 0221 were treated with weekly carboplatin and paclitaxel and radiation.
RESULTS: Survival was comparable for both studies and did not differ significantly across each trial after stratifying by HPV status. Grade 3 and 4 toxicities were more frequent in UMCC 9921. At 6 months posttreatment, gastrostomy tube (G-tube) dependence was not statistically different.
CONCLUSION: These data suggest that survival outcomes in patients with locally advanced SCCOP are not compromised with weekly chemotherapy and radiation therapy, and such treatment is generally more tolerable.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  HPV; chemoradiation; oropharynx; toxicity; weekly

Mesh:

Substances:

Year:  2013        PMID: 23596055      PMCID: PMC4205960          DOI: 10.1002/hed.23339

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  24 in total

1.  Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer.

Authors:  J P Pignon; J Bourhis; C Domenge; L Designé
Journal:  Lancet       Date:  2000-03-18       Impact factor: 79.321

2.  Optimal multivariate matching before randomization.

Authors:  Robert Greevy; Bo Lu; Jeffrey H Silber; Paul Rosenbaum
Journal:  Biostatistics       Date:  2004-04       Impact factor: 5.899

3.  Definitive radiochemotherapy of advanced head and neck cancer with carboplatin and paclitaxel : a phase II study.

Authors:  Robert Semrau; Susanne Temming; Simon Florian Preuss; Jens Peter Klubmann; Orlando Guntinas-Lichius; Rolf-Peter Müller
Journal:  Strahlenther Onkol       Date:  2011-09-23       Impact factor: 3.621

4.  Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: radiation therapy oncology group phase II trial 99-14.

Authors:  K Kian Ang; Jonathan Harris; Adam S Garden; Andy Trotti; Christopher U Jones; Luis Carrascosa; Jonathan D Cheng; Sharon S Spencer; Arlene Forastiere; Randal S Weber
Journal:  J Clin Oncol       Date:  2005-05-01       Impact factor: 44.544

5.  Phase II trial of hyperfractionated intensity-modulated radiation therapy and concurrent weekly cisplatin for Stage III and IVa head-and-neck cancer.

Authors:  Patrick D Maguire; Michael Papagikos; Sue Hamann; Charles Neal; Martin Meyerson; Neil Hayes; Peter Ungaro; Kenneth Kotz; Marion Couch; Hoke Pollock; Joel Tepper
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-04-08       Impact factor: 7.038

6.  Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients.

Authors:  Jean-Pierre Pignon; Aurélie le Maître; Emilie Maillard; Jean Bourhis
Journal:  Radiother Oncol       Date:  2009-05-14       Impact factor: 6.280

7.  Pharmacokinetics of cis-diamminedichloroplatinum (II) given as low-dose and high-dose infusions.

Authors:  N Kurihara; T Kubota; Y Hoshiya; Y Otani; N Ando; K Kumai; M Kitajima
Journal:  J Surg Oncol       Date:  1996-06       Impact factor: 3.454

8.  Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number.

Authors:  Francis P Worden; Bhavna Kumar; Julia S Lee; Gregory T Wolf; Kitrina G Cordell; Jeremy M G Taylor; Susan G Urba; Avraham Eisbruch; Theodoros N Teknos; Douglas B Chepeha; Mark E Prince; Christina I Tsien; Nisha J D'Silva; Kun Yang; David M Kurnit; Heidi L Mason; Tamara H Miller; Nancy E Wallace; Carol R Bradford; Thomas E Carey
Journal:  J Clin Oncol       Date:  2008-05-12       Impact factor: 44.544

9.  Concurrent chemoradiotherapy with weekly paclitaxel and carboplatin for locally advanced head and neck cancer: Long-term follow-up of a Brown University Oncology Group Phase II Study (HN-53).

Authors:  Prakash B Chougule; Muhammad S Akhtar; Ritesh Rathore; James Koness; Robert McRae; Peter Nigri; Kathie Radie-Keane; Teresa Kennedy; Harold J Wanebo; Neal Ready
Journal:  Head Neck       Date:  2008-03       Impact factor: 3.147

10.  Carboplatin and radiation therapy for stage IV carcinoma of the head and neck. Preliminary results of a phase II study.

Authors:  B Jeremic; D J Zivic; L J Djuric; L J Mijatovic
Journal:  J Chemother       Date:  1992-06       Impact factor: 1.714

View more
  7 in total

1.  Increased sensitivity of HPV-positive head and neck cancer cell lines to x-irradiation ± Cisplatin due to decreased expression of E6 and E7 oncoproteins and enhanced apoptosis.

Authors:  Frank Ziemann; Andrea Arenz; Stefanie Preising; Claus Wittekindt; Jens P Klussmann; Rita Engenhart-Cabillic; Andrea Wittig
Journal:  Am J Cancer Res       Date:  2015-02-15       Impact factor: 6.166

2.  Matted nodes as a predictor of distant metastasis in advanced-stage III/IV oropharyngeal squamous cell carcinoma.

Authors:  Matthew E Spector; Steven B Chinn; Emily Bellile; K Kelly Gallagher; Mohannad Ibrahim; Jeffrey Vainshtein; Eric J Chanowski; Heather M Walline; Jeffrey S Moyer; Mark E Prince; Gregory T Wolf; Carol R Bradford; Jonathan B McHugh; Thomas Carey; Francis P Worden; Avraham Eisbruch; Douglas B Chepeha
Journal:  Head Neck       Date:  2015-06-30       Impact factor: 3.147

Review 3.  Advanced oropharyngeal squamous cell carcinoma: Pathogenesis, treatment, and novel therapeutic approaches.

Authors:  Paul L Swiecicki; Kelly M Malloy; Francis P Worden
Journal:  World J Clin Oncol       Date:  2016-02-10

4.  Comparisons of dysphagia and quality of life (QOL) in comparable patients with HPV-positive oropharyngeal cancer receiving chemo-irradiation or cetuximab-irradiation.

Authors:  Stuart E Samuels; Yebin Tao; Teresa Lyden; Marc Haxer; Matthew Spector; Kelly M Malloy; Mark E Prince; Carol R Bradford; Francis P Worden; Matthew Schipper; Avraham Eisbruch
Journal:  Oral Oncol       Date:  2016-01-06       Impact factor: 5.337

Review 5.  Management of locally advanced HPV-related oropharyngeal squamous cell carcinoma: where are we?

Authors:  Stuart E Samuels; Avraham Eisbruch; Jonathan J Beitler; June Corry; Carol R Bradford; Nabil F Saba; Michiel W M van den Brekel; Robert Smee; Primož Strojan; Carlos Suárez; William M Mendenhall; Robert P Takes; Juan P Rodrigo; Missak Haigentz; Alexander D Rapidis; Alessandra Rinaldo; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-10-13       Impact factor: 3.236

6.  Comparing high-dose cisplatin with cisplatin-based combination chemotherapy in definitive concurrent chemoradiation setting for locally advanced head and neck squamous cell carcinoma (LAHNSCC).

Authors:  Muhammad Furqan; Travis P Snyders; Mohammed U Saqlain; Sarah L Mott; Douglas Laux; Anthony Snow; Carryn M Anderson; John M Watkins; Gerald H Clamon
Journal:  Cancer Med       Date:  2019-04-09       Impact factor: 4.452

7.  Chemoradiotherapy with high-dose cisplatin compared with weekly cisplatin for locally advanced head and neck squamous cell carcinoma.

Authors:  Ryan T Hughes; Mercedes Porosnicu; Beverly J Levine; Thomas W Lycan; Rachel F Shenker; Bart A Frizzell; Kathryn M Greven
Journal:  J Med Imaging Radiat Oncol       Date:  2021-07-26       Impact factor: 1.667

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.